Skip to main content

Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia

International Journal of Hematology volume 112, pages 24–32 (2020)Cite this article

Abstract

This open-label, single-arm, phase 2 study (ClinicalTrials.gov, NCT03128411) evaluated the efficacy, safety, and pharmacokinetics of bosutinib at a starting dose of 400 mg once daily (QD) in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML). The primary endpoint was major molecular response (MMR) at Month 12 in the modified as-treated population (Philadelphia chromosome-positive [Ph+] patients with e13a2/e14a2 transcripts). Sixty Japanese patients with CP CML were treated with bosutinib; median age was 55 years (range 20–83), 60.0% were males, and all were Ph+ and had e13a2/e14a2 transcripts. After median follow-up of 16.6 months (range 11.1–21.9), 41 (68.3%) patients remained on bosutinib. The MMR rate at Month 12 was 55.0% (2-sided 90% confidence interval: 44.4–65.6). There were no on-treatment transformations to accelerated/blast phase, and no patient died on treatment or within 28 days of the last bosutinib dose. The most common treatment-emergent adverse events were diarrhea (86.7%), increased alanine aminotransferase (55.0%), and increased aspartate aminotransferase (46.7%). The primary objective of this phase 2 study was met, and there were no new safety signals for bosutinib. These data suggest bosutinib is an effective first-line treatment option for Japanese patients with newly diagnosed CP CML.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

Data availability

Upon request, and subject to certain criteria, conditions and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

References

  1. Pfizer Inc. Bosulif® (bosutinib) prescribing information. 2012 (last update: Dec 2017). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203341s009lbl.pdf. Accessed 11 Nov 2019.

  2. European Medicines Agency. Bosulif® (bosutinib) summary of product characteristics. 2013 (last update: Aug 7, 2019). https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif. Accessed 11 Nov 2019.

  3. Pfizer Japan Inc. Bosulif® (bosutinib hydrate) prescribing information. Japan; 2017.

  4. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–7.

    CAS  Article  Google Scholar 

  5. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567–76.

    CAS  Article  Google Scholar 

  6. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119:3403–12.

    CAS  Article  Google Scholar 

  7. Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486–92.

    CAS  Article  Google Scholar 

  8. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.

    CAS  Article  Google Scholar 

  9. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. 2010 (last update: Jun 14, 2010). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 11 Nov 2019.

  10. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.

    CAS  Article  Google Scholar 

  11. Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89:14–23.

    Article  Google Scholar 

  12. Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, et al. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res. 2010;34:1459–71.

    Article  Google Scholar 

  13. Jootar S. CML treatment in Asia-Pacific region. Hematology. 2012;17(Suppl 1):S72–S7474.

    Article  Google Scholar 

  14. Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, et al. A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. Int J Hematol. 2015;101:154–64.

    CAS  Article  Google Scholar 

  15. Deininger MW, Kota V, Lipton JH, Milojkovic D, García Gutiérrez V, Leip E, et al. Bosutinib or imatinib in older vs younger patients with newly diagnosed chronic myeloid leukemia in the phase 3 BFORE trial. Blood. 2018;132:1734.

    Article  Google Scholar 

  16. Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168:69–81.

    Article  Google Scholar 

  17. Hsyu PH, Mould DR, Upton RN, Amantea M. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol. 2013;71:209–18.

    CAS  Article  Google Scholar 

  18. Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, et al. Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Exp Hematol Oncol. 2018;7:9.

    Article  Google Scholar 

  19. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.

    CAS  Article  Google Scholar 

  20. Khoury HJ, Gambacorti-Passerini C, Brummendorf TH. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Ann Oncol. 2018;29:578–87.

    CAS  Article  Google Scholar 

  21. Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018;11:143.

    CAS  Article  Google Scholar 

  22. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brummendorf TH, Porkka K, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309–18.

    CAS  Article  Google Scholar 

  23. Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematol Am Soc Hematol Educ Program. 2017;2017:110–4.

    Article  Google Scholar 

  24. Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. Blood Rev. 2018;32:289–99.

    CAS  Article  Google Scholar 

  25. Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, et al. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018;97:2081–8.

    CAS  Article  Google Scholar 

  26. Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol. 2014;99:141–53.

    CAS  Article  Google Scholar 

  27. Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105:792–804.

    CAS  Article  Google Scholar 

  28. Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93:624–32.

    CAS  Article  Google Scholar 

  29. Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2018;107:327–36.

    CAS  Article  Google Scholar 

  30. Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, et al. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019;109:426–39.

    CAS  Article  Google Scholar 

  31. Goldberg SL, Savona M, Mauro MJ. Considerations for successful treatment-free remission in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18:98–105.

    Article  Google Scholar 

  32. Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846–54.

    CAS  Article  Google Scholar 

  33. Ross DM, Masszi T, Gomez Casares MT, Hellmann A, Stentoft J, Conneally E, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018;144:945–54.

    CAS  Article  Google Scholar 

  34. Mahon FX, Hughes TP. Treatment-free remission after second-line nilotinib treatment. Ann Intern Med. 2018;169:510.

    Article  Google Scholar 

  35. Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk. 2018;18(353–60):e1.

    Google Scholar 

  36. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–57.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This study was sponsored by Pfizer. Medical writing support was provided by Joanna Bloom, PhD, of Engage Scientific Solutions and was funded by Pfizer.

Author information

Authors and Affiliations

  1. Department of Hematology, Osaka City University Hospital, 1-4-3, Asahi-machi, Abeno-ku, Osaka, Japan

    Masayuki Hino

  2. Kindai University Hospital, Osaka, Japan

    Itaru Matsumura

  3. Yokohama City University Medical Center, Yokohama, Japan

    Shin Fujisawa

  4. Yamagata University Hospital, Yamagata, Japan

    Kenichi Ishizawa

  5. Hamamatsu University Hospital, Shizuoka, Japan

    Takaaki Ono

  6. Chiba University Hospital, Chiba, Japan

    Emiko Sakaida

  7. National Hospital Organization Disaster Medical Center, Tokyo, Japan

    Naohiro Sekiguchi

  8. Pfizer R&D Japan GK, Tokyo, Japan

    Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura & Yuichiro Koide

  9. Akita University Hospital, Akita, Japan

    Naoto Takahashi

Authors
  1. Masayuki Hino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Itaru Matsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shin Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenichi Ishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takaaki Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emiko Sakaida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naohiro Sekiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yusuke Tanetsugu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kei Fukuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masayuki Ohkura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yuichiro Koide
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Naoto Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Hino.

Ethics declarations

Conflict of interest

Masayuki Hino reports research funding from Pfizer, Novartis, and Otsuka, and honoraria from Pfizer, Novartis, Otsuka, and Bristol-Myers Squibb. Itaru Matsumura reports research funding from Pfizer and Otsuka, speakers bureau with Novartis and Bristol-Myers Squibb, and consultancy with Otsuka. Shin Fujisawa reports honoraria and research funding from Novartis, Pfizer, Otsuka, and Bristol-Myers Squibb. Kenichi Ishizawa reports research funding from Pfizer and Otsuka and speakers bureau with Novartis and Bristol-Myers Squibb. Takaaki Ono reports honoraria from Celgene, Merck Sharp & Dohme, Ono, Novartis, Bristol-Myers Squibb, Pfizer, Otsuka, and Takeda and research funding from, Celgene, Merck Sharp & Dohme, Ono, Kyowa Hakko Kirin, and Chugai. Emiko Sakaida reports research funding from Bristol-Myers Squibb, Chugai, Ono, and Kyowa Kirin. Naohiro Sekiguchi reports research funding from Ono, A2 Healthcare, Astellas, Janssen, Merck Sharp & Dohme, Otsuka, Pfizer, PPD-SNBL, Sumitomo Dainippon Pharma, Daiichi Sankyo Company, and Bristol-Myers Squibb. Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura, and Yuichiro Koide report employment by Pfizer R&D Japan G.K. Naoto Takahashi reports research funding and honoraria from Pfizer, Otsuka, and Novartis, and research funding from Chugai, Eizai, Asahikasei, Ono, Kyowahakko-Kirin, and Toyamakagaku, outside the submitted work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 199 kb)

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hino, M., Matsumura, I., Fujisawa, S. et al. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. Int J Hematol 112, 24–32 (2020). https://doi.org/10.1007/s12185-020-02878-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02878-x

Keywords

  • Bosutinib
  • Tyrosine kinase inhibitor
  • Chronic myeloid leukemia
  • Japan